DLA Piper advises on Nsing Tech’s Hong Kong IPO and H share listing

Global law firm DLA Piper has advised Nsing Technologies Inc. (Nsing Tech) (A Share: SHE: 300077) a leading Chinese platform-based integrated circuit design company, on its Initial Public Offering (IPO) and H share listing on the Main Board of the Hong Kong Stock Exchange (HKEX), helping it achieve an “A+H” dual listing, raising HKD1.03 billion (approximately USD131.2 million).

Founded in 2000 in Shenzhen, Nsing Tech specializes in control chips and system solutions for intelligent terminals, with a diversified business model that also includes a lithium-ion battery anode material business. The proceeds from this H share listing will primarily fund research and development. Leveraging the advantages of its dual A+H capital platform, the company will focus on new technology platforms, high-performance microcontroller units (MCUs), and automotive-grade semiconductors. The capital raised will also support strategic investments and acquisitions across the semiconductor value chain, focusing on its core business layout to further strengthen the company’s competitive position in AIoT, and energy applications.

The listing marks a major milestone for Nsing Tech, one of China’s top five platform-oriented MCU designers, as it strengthens its capital base and expands its footprint in consumer electronics, AIoT, edge intelligence, and automotive electronics. The IPO offers H-shares, broadening the company’s international investor base and reinforcing its financial position amid growing demand for domestic chip self-sufficiency and high-performance MCUs.

The DLA Piper team was led by Sherlyn Lau, Head of Capital Markets and Corporate Finance, APAC. She was supported by Iris Yuen and Jacob Zhao (both of counsels), Maggie Bai (registered foreign lawyer), Hannah Wong (senior corporate manager) and Wendy Ho (senior legal officer), all part of the firm’s Corporate practice in Hong Kong.

Commenting on the transaction, Sherlyn said: “This successful listing underscores Nsing Tech’s vision and ambition, and we are proud to have played a role in bringing it to fruition. For me, it is a particularly meaningful milestone as the first IPO I have advised on since joining DLA Piper, and it reflects the breadth and strength of the firm’s Capital Markets team in Hong Kong.”

In recent months, DLA Piper’s Capital Markets team has advised on several high-profile Hong Kong IPOs including biopharmaceutical companies B&K Corporation and Xuanzhu Biopharmaceutical, 160 Health – China’s leading digital healthcare integrated service provider, Xunfei Healthcare Technology and Chifeng Jilong Gold Mining Company.